Skip to main content
Premium Trial:

Request an Annual Quote

Cancer Dx Firm Metamark Genetics Raises $22M

This article has been updated with additional information from a company statement.

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cancer diagnostics startup Metamark Genetics has raised about $22 million in a Series B round of financing, it disclosed in a document filed with the US Securities and Exchange Commission.

The company is targeting about $42 million in total, it said. Among the participants in the round were directors and executives at the Cambridge, Mass.-based firm, which said that it intends the offering to last more than one year. It is not related to a business combination transaction, such as a merger, acquisition, or exchange offer, Metamark said in its filing.

Metamark said in a statement released today that the lead investor in the round has an obligation to purchase up to an aggregate of $8 million of additional preferred stock.

Proceeds will be used to expand Metamark's research and development efforts and clinical testing infrastructure, and establish its commercial organization, the firm said.

Metamark was founded in 2007 and develops diagnostic tests to "enable personalized treatment planning for cancer patients, improved outcomes, and reduced healthcare costs," according to its website. Its lead platform is the Prognosis Determinants system, based on research in melanoma by Lynda Chin at the Dana-Farber Cancer Institute and Harvard Medical School. Chin is also a director of Metamark.

Using the platform, Metamark said it has identified and validated functionally active genetic determinants of metastasis "critical to the progression of a broad spectrum of tumor types." The company is developing diagnostic assays based on its discoveries.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.